CYP450 2D6 Genotype and Flecainide Efficacy in the Treatment of Patients with Lone Atrial Fibrillation

@article{Fuchs2012CYP4502G,
  title={CYP450 2D6 Genotype and Flecainide Efficacy in the Treatment of Patients with Lone Atrial Fibrillation},
  author={T. Fuchs and E. Baron and A. Bar-Haim and Patricia Benveniste-Levkovitz and A. Torjman and Moshe Sharist and M. Leitman and Shmuel Bar-Haim},
  journal={Hospital chronicles},
  year={2012},
  volume={7},
  pages={229-233}
}
  • T. Fuchs, E. Baron, +5 authors Shmuel Bar-Haim
  • Published 2012
  • Medicine
  • Hospital chronicles
  • Background : CYP2D6 has been linked to one of four phenotypes: a) ultra-rapid metabolizers (UM), with multiple gene copies; b) extensive metabolizers (EM), with a single wild type gene copy, considered normal; c) intermediate (IM) metabolizer, with decreased enzymatic activity; and d) poor metabolizers (PM) with no detectable enzymatic activity.  By altering the drug dose-plasma concentration relationship, these differences may lead to severe toxicity and or therapeutic failure. Objectives… CONTINUE READING

    References

    SHOWING 1-10 OF 22 REFERENCES
    Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia
    • 23
    Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
    • 344
    • Highly Influential
    The AmpliChip™ CYP450 Genotyping Test
    • 62
    The AmpliChip CYP450 test: principles, challenges, and future clinical utility in digestive disease.
    • B. Juran, L. Egan, K. N. Lazaridis
    • Medicine
    • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
    • 2006
    • 18
    Potent Inhibition of Cytochrome P450IID6 (Debrisoquin 4‐Hydroxylase) by Flecainide In Vitro and In Vivo
    • 42
    Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia
    • 12